Expression of MUC1 in different tumours and its clinical significance (Review)
- Authors:
- Yue Lan
- Weihua Ni
- Guixiang Tai
-
Affiliations: Department of Immunology, College of Basic Medical Science, Jilin University, Changchun, Jilin 130021, P.R. China - Published online on: November 1, 2022 https://doi.org/10.3892/mco.2022.2594
- Article Number: 161
-
Copyright: © Lan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Wi DH, Cha JH and Jung YS: Mucin in cancer: A stealth cloak for cancer cells. BMB Rep. 54:344–355. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Xu F, Liu F, Zhao H, An G and Feng G: Prognostic significance of mucin antigen MUC1 in various human epithelial cancers: A meta-analysis. Medicine (Baltimore). 94(e2286)2015.PubMed/NCBI View Article : Google Scholar | |
|
Bose M, Grover P, Sanders AJ, Zhou R, Ahmad M, Shwartz S, Lala P, Nath S, Yazdanifar M, Brouwer C and Mukherjee P: Overexpression of MUC1 induces non-canonical TGF-β signaling in pancreatic ductal adenocarcinoma. Front Cell Dev Biol. 10(821875)2022.PubMed/NCBI View Article : Google Scholar | |
|
Khodabakhsh F, Merikhian P, Eisavand MR and Farahmand L: Crosstalk between MUC1 and VEGF in angiogenesis and metastasis: A review highlighting roles of the MUC1 with an emphasis on metastatic and angiogenic signaling. Cancer Cell Int. 21(200)2021.PubMed/NCBI View Article : Google Scholar | |
|
Supruniuk K and Radziejewska I: MUC1 is an oncoprotein with a significant role in apoptosis (Review). Int J Oncol. 59(68)2021.PubMed/NCBI View Article : Google Scholar | |
|
Chen W, Zhang Z, Zhang S, Zhu P, Ko JK and Yung KK: MUC1: Structure, function, and clinic application in epithelial cancers. Int J Mol Sci. 22(6567)2021.PubMed/NCBI View Article : Google Scholar | |
|
Beatty PL and Finn OJ: Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas. Ann N Y Acad Sci. 1284:52–56. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Guo M, You C and Dou J: Role of transmembrane glycoprotein mucin 1 (MUC1) in various types of colorectal cancer and therapies: Current research status and updates. Biomed Pharmacother. 107:1318–1325. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Cascio S and Finn OJ: Intra- and extra-cellular events related to altered glycosylation of MUC1 promote chronic inflammation, tumor progression, invasion, and metastasis. Biomolecules. 6(39)2016.PubMed/NCBI View Article : Google Scholar | |
|
Gao T, Cen Q and Lei H: A review on development of MUC1-based cancer vaccine. Biomed Pharmacother. 132(110888)2020.PubMed/NCBI View Article : Google Scholar | |
|
Li W, Han Y, Sun C, Li X, Zheng J, Che J, Yao X and Kufe D: Novel insights into the roles and therapeutic implications of MUC1 oncoprotein via regulating proteins and non-coding RNAs in cancer. Theranostics. 12:999–1011. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Hagiwara M, Fushimi A, Bhattacharya A, Yamashita N, Morimoto Y, Oya M, Withers HG, Hu Q, Liu T, Liu S, et al: MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer. Oncoimmunology. 11(2029298)2022.PubMed/NCBI View Article : Google Scholar | |
|
Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, et al: MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nat Commun. 11(338)2020.PubMed/NCBI View Article : Google Scholar | |
|
Hosseinzadeh A, Merikhian P, Naseri N, Eisavand MR and Farahmand L: MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy. Cancer Cell Int. 22(110)2022.PubMed/NCBI View Article : Google Scholar | |
|
Utispan K and Koontongkaew S: Mucin 1 regulates the hypoxia response in head and neck cancer cells. J Pharmacol Sci. 147:331–339. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesna A, Kazarnowicz A, et al: TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): Results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncol. 17:212–223. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Ning Y, Zheng H, Zhan Y, Liu S, Yang Y, Zang H, Luo J, Wen Q and Fan S: Comprehensive analysis of the mechanism and treatment significance of Mucins in lung cancer. J Exp Clin Cancer Res. 39(162)2020.PubMed/NCBI View Article : Google Scholar | |
|
Kwan TY and Chowdhury EH: Clinical outcomes of chemotherapeutic molecules as single and multiple agents in advanced non-small-cell lung carcinoma (NSCLC) patients. Medicina (Kaunas). 57(1252)2021.PubMed/NCBI View Article : Google Scholar | |
|
Kaira K, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Endo M, Kondo H, Nakajima T and Yamamoto N: Depolarized MUC1 expression is closely associated with hypoxic markers and poor outcome in resected non-small cell lung cancer. Int J Surg Pathol. 20:223–232. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Situ D, Wang J, Ma Y, Zhu Z, Hu Y, Long H and Rong T: Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer. Med Oncol. 28 (Suppl 1):S596–S604. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Palladino P, Papi F, Minunni M, Nativi C and Scarano S: Structurally constrained MUC1-tn mimetic antigen as template for molecularly imprinted polymers (MIPs): A promising tool for cancer diagnostics. Chempluschem. 87(e202200068)2022.PubMed/NCBI View Article : Google Scholar | |
|
Kato T, Ujiie H, Hatanaka KC, Nange A, Okumura A, Tsubame K, Naruchi K, Sato M, Kaga K, Matsuno Y, et al: A novel Tn antigen epitope-recognizing antibody for MUC1 predicts clinical outcome in patients with primary lung adenocarcinoma. Oncol Lett. 21(202)2021.PubMed/NCBI View Article : Google Scholar | |
|
Xie Q, Zhao S, Liu W, Cui Y, Li F, Li Z, Guo T, Yu W, Guo W, Deng W and Gu C: YBX1 enhances metastasis and stemness by transcriptionally regulating MUC1 in lung adenocarcinoma. Front Oncol. 11(702491)2021.PubMed/NCBI View Article : Google Scholar | |
|
Liu S, Zhang X, Jiang Q and Liang T: Detection of circulating natural antibodies against CD25, MUC1, and VEGFR1 for early diagnosis of non-small cell lung cancer. FEBS Open Bio. 10:1288–1294. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Warawdekar UM, Sirajuddin MM, Pramesh CS and Mistry RC: An approach of selecting appropriate markers from the primary tumor to enable detection of circulating tumor cells in patients with non-small cell lung cancer. J BUON. 20:782–790. 2015.PubMed/NCBI | |
|
Li J, Hu YM, Du YJ, Zhu LR, Qian H, Wu Y and Shi WL: Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer. BMC Cancer. 14(848)2014.PubMed/NCBI View Article : Google Scholar | |
|
Savarese-Brenner B, Heugl M, Rath B, Schweizer C, Obermayr E, Stickler S and Hamilton G: MUC1 and CD147 are promising markers for the detection of circulating tumor cells in small cell lung cancer. Anticancer Res. 42:429–439. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Borri F and Granaglia A: Pathology of triple negative breast cancer. Semin Cancer Biol. 72:136–145. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Siroy A, Abdul-Karim FW, Miedler J, Fong N, Fu P, Gilmore H and Baar J: MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer. Hum Pathol. 44:2159–2166. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Maeda T, Hiraki M, Jin C, Rajabi H, Tagde A, Alam M, Bouillez A, Hu X, Suzuki Y, Miyo M, et al: MUC1-C induces PD-L1 and immune evasion in triple-negative breast cancer. Cancer Res. 78:205–215. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Yamashita N, Long M, Fushimi A, Yamamoto M, Hata T, Hagiwara M, Bhattacharya A, Hu Q, Wong KK, Liu S and Kufe D: MUC1-C integrates activation of the IFN-gamma pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer. J Immunother Cancer. 9(e002115)2021.PubMed/NCBI View Article : Google Scholar | |
|
Laidi F, Bouziane A, Errachid A and Zaoui F: Usefulness of salivary and serum auto-antibodies against tumor biomarkers HER2 and MUC1 in breast cancer screening. Asian Pac J Cancer Prev. 17:335–339. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Cheng JP, Yan Y, Wang XY, Lu YL, Yuan YH, Jia J and Ren J: MUC1-positive circulating tumor cells and MUC1 protein predict chemotherapeutic efficacy in the treatment of metastatic breast cancer. Chin J Cancer. 30:54–61. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Jing X, Liang H, Hao C, Yang X and Cui X: Overexpression of MUC1 predicts poor prognosis in patients with breast cancer. Oncol Rep. 41:801–810. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Li J, Liu L, Feng Z, Wang X, Huang Y, Dai H, Zhang L, Song F, Wang D, Zhang P, et al: Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: A cohort study. Breast Cancer. 27:621–630. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Gaitskell K, Hermon C, Barnes I, Pirie K, Floud S, Green J, Beral V and Reeves GK: Million Women Study Collaborators. Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK million women study. Cancer Epidemiol. 76(102074)2022.PubMed/NCBI View Article : Google Scholar | |
|
Ma Q, Song J, Wang S and He N: MUC1 regulates AKT signaling pathway by upregulating EGFR expression in ovarian cancer cells. Pathol Res Pract. 224(153509)2021.PubMed/NCBI View Article : Google Scholar | |
|
Budiu RA, Mantia-Smaldone G, Elishaev E, Chu T, Thaller J, McCabe K, Lenzner D, Edwards RP and Vlad AM: Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Cancer Immunol Immunother. 60:975–984. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Wang L, Ma J, Liu F, Yu Q, Chu G, Perkins AC and Li Y: Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecol Oncol. 105:695–702. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Barani M, Bilal M, Sabir F, Rahdar A and Kyzas GZ: Nanotechnology in ovarian cancer: Diagnosis and treatment. Life Sci. 266(118914)2021.PubMed/NCBI View Article : Google Scholar | |
|
Hu XF, Yang E, Li J and Xing PX: MUC1 cytoplasmic tail: A potential therapeutic target for ovarian carcinoma. Expert Rev Anticancer Ther. 6:1261–1271. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Elvevi A, Laffusa A, Scaravaglio M, Rossi RE, Longarini R, Stagno AM, Cristoferi L, Ciaccio A, Cortinovis DL, Invernizzi P and Massironi S: Clinical treatment of cholangiocarcinoma: An updated comprehensive review. Ann Hepatol. 27(100737)2022.PubMed/NCBI View Article : Google Scholar | |
|
Park SY, Roh SJ, Kim YN, Kim SZ, Park HS, Jang KY, Chung MJ, Kang MJ, Lee DG and Moon WS: Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: Prognostic impact. Oncol Rep. 22:649–657. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Mall AS, Tyler MG, Ho SB, Krige JEJ, Kahn D, Spearman W, Myer L and Govender D: The expression of MUC mucin in cholangiocarcinoma. Pathol Res Pract. 206:805–809. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Chen FY, Zhou C, Zhang XY, Zhou KQ, Peng YF, Yu L, Fan J, Zhou J, Hu J and Wang Z: Integrated Bioinformatics analysis and clinical validation reveals that high expression of mucin 1 in intrahepatic cholangiocarcinoma predicts recurrence after curative resection. Exp Ther Med. 20(50)2020.PubMed/NCBI View Article : Google Scholar | |
|
Matsumura N, Yamamoto M, Aruga A, Takasaki K and Nakano M: Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma. Cancer. 94:1770–1776. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Supimon K, Sangsuwannukul T, Sujjitjoon J, Phanthaphol N, Chieochansin T, Poungvarin N, Wongkham S, Junking M and Yenchitsomanus PT: Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma. Sci Rep. 11(6276)2021.PubMed/NCBI View Article : Google Scholar | |
|
Bosch DE, Salipante SJ, Schmidt RA, Swanson PE, Bryan A, SenGupta DJ, Truong CD and Yeh MM: Neutrophilic inflammation in gallbladder carcinoma correlates with patient survival: A case-control study. Ann Diagn Pathol. 56(151845)2022.PubMed/NCBI View Article : Google Scholar | |
|
Garcia P, Bizama C, Rosa L, Espinoza JA, Weber H, Cerda-Infante J, Sánchez M, Montecinos VP, Lorenzo-Bermejo J, Boekstegers F, et al: Functional and genomic characterization of three novel cell lines derived from a metastatic gallbladder cancer tumor. Biol Res. 53(13)2020.PubMed/NCBI View Article : Google Scholar | |
|
Bhoge A, Khandeparkar SGS, Joshi AR, Gogate B, Kulkarni MM and Bhayekar P: Immunohistochemical study of MUC1 and MUC5AC expression in gall bladder lesions. J Clin Diagn Res. 11:EC12–EC16. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Xiong L, Yang Z, Yang L, Liu J and Miao X: Expressive levels of MUC1 and MUC5AC and their clinicopathologic significances in the benign and malignant lesions of gallbladder. J Surg Oncol. 105:97–103. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Kaur S, Momi N, Chakraborty S, Wagner DG, Horn AJ, Lele SM, Theodorescu D and Batra SK: Altered expression of transmembrane mucins, MUC1 and MUC4, in bladder cancer: Pathological implications in diagnosis. PLoS One. 9(e92742)2014.PubMed/NCBI View Article : Google Scholar | |
|
Stojnev S, Ristic-Petrovic A, Velickovic LJ, Krstic M, Bogdanovic D, Khanh DT, Ristic A, Conic I and Stefanovic V: Prognostic significance of mucin expression in urothelial bladder cancer. Int J Clin Exp Pathol. 7:4945–4958. 2014.PubMed/NCBI | |
|
Gonul II, Cakir A and Sozen S: Immunohistochemical expression profiles of MUC1 and MUC2 mucins in urothelial tumors of bladder. Indian J Pathol Microbiol. 61:350–355. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Tao TT, Chen J, Hu Q, Huang XZ, Fu J, Lv BD and Duan Y: Urothelial carcinoma of the bladder with abundant myxoid stroma: A case report and literature review. Medicine (Baltimore). 99(e21204)2020.PubMed/NCBI View Article : Google Scholar | |
|
Shigeta K, Hasegawa M, Kikuchi E, Yasumizu Y, Kosaka T, Mizuno R, Mikami S, Miyajima A, Kufe D and Oya M: Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma. Cancer Sci. 111:3639–3652. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Anwanwan D, Singh SK, Singh S, Saikam V and Singh R: Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 1873(188314)2020.PubMed/NCBI View Article : Google Scholar | |
|
Yuan SF, Li KZ, Wang L, Dou KF, Yan Z, Han W and Zhang YQ: Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue. World J Gastroenterol. 11:4661–4666. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Ichikawa T, Yamamoto T, Uenishi T, Tanaka H, Takemura S, Ogawa M, Tanaka S, Suehiro S, Hirohashi K and Kubo S: Clinicopathological implications of immunohistochemically demonstrated mucin core protein expression in hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 13:245–251. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Jiang QL, Feng SJ, Yang ZY, Xu Q and Wang SZ: CircHECTD1 up-regulates mucin 1 expression to accelerate hepatocellular carcinoma development by targeting microRNA-485-5p via a competing endogenous RNA mechanism. Chin Med J (Engl). 133:1774–1785. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Morari EC, Silva JR, Guilhen AC, Cunha LL, Marcello MA, Soares FA, Vassallo J and Ward LS: Muc-1 expression may help characterize thyroid nodules but does not predict patients' outcome. Endocr Pathol. 21:242–249. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Zhan XX, Zhao B, Diao C, Cao Y and Cheng RC: Expression of MUC1 and CD176 (Thomsen-Friedenreich antigen) in papillary thyroid carcinomas. Endocr Pathol. 26:21–26. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Hu YJ, Luo XY, Yang Y, Chen CY, Zhang ZY and Guo X: Characterization and significance of MUC1 and c-myc expression in elderly patients with papillary thyroid carcinoma. Genet Mol Res. 14:15325–15330. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simões M, Tallini G and Mete O: Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol. 33:27–63. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Baek SK, Woo JS, Kwon SY, Lee SH, Chae YS and Jung KY: Prognostic significance of the MUC1 and MUC4 expressions in thyroid papillary carcinoma. Laryngoscope. 117:911–916. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Guo M, Luo B, Pan M, Li M, Xu H, Zhao F and Dou J: Colorectal cancer stem cell vaccine with high expression of MUC1 serves as a novel prophylactic vaccine for colorectal cancer. Int Immunopharmacol. 88(106850)2020.PubMed/NCBI View Article : Google Scholar | |
|
Guo M, You C, Dong W, Luo B, Wu Y, Chen Y, Li J, Pan M, Li M, Zhao F and Dou J: The surface dominant antigen MUC1 is required for colorectal cancer stem cell vaccine to exert anti-tumor efficacy. Biomed Pharmacother. 132(110804)2020.PubMed/NCBI View Article : Google Scholar | |
|
Wang HS and Wang LH: The expression and significance of Gal-3 and MUC1 in colorectal cancer and colon cancer. Onco Targets Ther. 8:1893–1898. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Kasprzak A, Siodla E, Andrzejewska M, Szmeja J, Seraszek-Jaros A, Cofta S and Szaflarski W: Differential expression of mucin 1 and mucin 2 in colorectal cancer. World J Gastroenterol. 24:4164–4177. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Hazgui M, Weslati M, Boughriba R, Ounissi D, Bacha D and Bouraoui S: MUC1 and MUC5AC implication in Tunisian colorectal cancer patients. Turk J Med Sci. 51:309–318. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Niv Y and Rokkas T: Mucin expression in colorectal cancer (CRC): Systematic review and meta-analysis. J Clin Gastroenterol. 53:434–440. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Schimanski CC, Kasper S, Hegewisch-Becker S, Schröder J, Overkamp F, Kullmann F, Bechstein WO, Vöhringer M, Öllinger R, Lordick F, et al: Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: A randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC). Oncoimmunology. 9(1806680)2020.PubMed/NCBI View Article : Google Scholar | |
|
Shimada M, Tsuji K, Shigeta S, Nagai T, Watanabe Z, Tokunaga H, Kigawa J and Yaegashi N: Rethinking the significance of surgery for uterine cervical cancer. J Obstet Gynaecol Res. 48:576–586. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Togami S, Nomoto M, Higashi M, Goto M, Yonezawa S, Tsuji T, Batra SK and Douchi T: Expression of mucin antigens (MUC1 and MUC16) as a prognostic factor for mucinous adenocarcinoma of the uterine cervix. J Obstet Gynaecol Res. 36:588–597. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Gardner AB, Charo LM, Mann AK, Kapp DS, Eskander RN and Chan JK: Ovarian, uterine, and cervical cancer patients with distant metastases at diagnosis: Most common locations and outcomes. Clin Exp Metastasis. 37:107–113. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Samouëlian V, Mechtouf N, Leblanc E, Cardin GB, Lhotellier V, Querleu D, Révillion F and Rodier F: Sensitive molecular detection of small nodal metastasis in uterine cervical cancer using HPV16-E6/CK19/MUC1 cancer biomarkers. Oncotarget. 9:21641–21654. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Cai J, Chen H, Lu M, Zhang Y, Lu B, You L, Zhang T, Dai M and Zhao Y: Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis. Cancer Lett. 520:1–11. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Wang S, You L, Dai M and Zhao Y: Mucins in pancreatic cancer: A well-established but promising family for diagnosis, prognosis and therapy. J Cell Mol Med. 24:10279–10289. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Fu X, Tang N, Xie WQ, Mao L and Qiu YD: MUC1 promotes glycolysis through inhibiting BRCA1 expression in pancreatic cancer. Chin J Nat Med. 18:178–185. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Sierzega M, Mlynarski D, Tomaszewska R and Kulig J: Semiquantitative immunohistochemistry for mucin (MUC1, MUC2, MUC3, MUC4, MUC5AC, and MUC6) profiling of pancreatic ductal cell adenocarcinoma improves diagnostic and prognostic performance. Histopathology. 69:582–591. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Maleki F, Rezazadeh F and Varmira K: MUC1-targeted radiopharmaceuticals in cancer imaging and therapy. Mol Pharm. 18:1842–1861. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Alirezapour B, Ashkezari MD, Fini MM, Rasaee MJ, Mohammadnejad J, Paknejad M, Maadi E, Yousefnia H and Zolghadri S: Preparation and preclinical characterization of (111)In-DTPA-Anti-MUC1 as a radioimmunoconjugate for diagnosis of breast cancer by single-photon emission computed tomography. J Cancer Res Ther. 18:158–167. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Stergiou N, Nagel J, Pektor S, Heimes AS, Jäkel J, Brenner W, Schmidt M, Miederer M, Kunz H, Roesch F and Schmitt E: Evaluation of a novel monoclonal antibody against tumor-sassociated MUC1 for diagnosis and prognosis of breast cancer. Int J Med Sci. 16:1188–1198. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Pierga JY, Bidard FC, Denis MG and de Cremoux P: Prognostic value of peripheral blood double detection of CK19 and MUC1 mRNA positive cells detected by RT-quantitative PCR in 94 breast cancer patients with a follow up of 9 years. Mol Oncol. 1:267–268. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Liu C, Xie Y, Sun B, Geng F, Zhang F, Guo Q, Wu H, Yu B, Wu J, Yu X, et al: MUC1- and survivin-based DNA vaccine combining immunoadjuvants CpG and interleukin-2 in a bicistronic expression plasmid generates specific immune responses and antitumour effects in a murine colorectal carcinoma model. Scand J Immunol. 87:63–72. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Ruan J, Duan Y, Li F and Wang Z: Enhanced synergistic anti-Lewis lung carcinoma effect of a DNA vaccine harboring a MUC1-VEGFR2 fusion gene used with GM-CSF as an adjuvant. Clin Exp Pharmacol Physiol. 44:71–78. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Gong YF, Zhou QB, Liao YD, Mai C, Chen TJ, Tang YQ and Chen RF: Optimized construction of MUC1-VNTRn DNA vaccine and its anti-pancreatic cancer efficacy. Oncol Lett. 13:2198–2206. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Ogasawara M, Miyashita M, Yamagishi Y and Ota S: Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: A single-center phase I/II trial. Ther Apher Dial. 25:415–424. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Ota S, Miyashita M, Yamagishi Y and Ogasawara M: Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy. Hum Vaccin Immunother. 17:5563–5572. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Tosch C, Bastien B, Barraud L, Grellier B, Nourtier V, Gantzer M, Limacher JM, Quemeneur E, Bendjama K and Préville X: Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC. J Immunother Cancer. 5(70)2017.PubMed/NCBI View Article : Google Scholar | |
|
Glaffig M, Stergiou N, Hartmann S, Schmitt E and Kunz H: A synthetic MUC1 anticancer vaccine containing mannose ligands for targeting macrophages and dendritic cells. ChemMedChem. 13:25–29. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Hu B, Wang J, Guo Y, Chen T, Ni W, Yuan H, Zhang N, Xie F and Tai G: Pre-clinical toxicity and immunogenicity evaluation of a MUC1-MBP/BCG anti-tumor vaccine. Int Immunopharmacol. 33:108–118. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Zhang H, Zhao H, He X, Xi F and Liu J: JAK-STAT domain enhanced MUC1-CAR-T cells induced esophageal cancer elimination. Cancer Manag Res. 12:9813–9824. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Mei Z, Zhang K, Lam AK, Huang J, Qiu F, Qiao B and Zhang Y: MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma. Cancer Med. 9:640–652. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Zhou R, Yazdanifar M, Roy LD, Whilding LM, Gavrill A, Maher J and Mukherjee P: CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Front Immunol. 10(1149)2019.PubMed/NCBI View Article : Google Scholar | |
|
Pang L, Wang J, Fan Y, Xu R, Bai Y and Bai L: Correlations of TNM staging and lymph node metastasis of gastric cancer with MRI features and VEGF expression. Cancer Biomark. 23:53–59. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Jeong O, Jung MR and Kang JH: Prognostic value of the anatomic region of metastatic lymph nodes in the current TNM staging of gastric cancer. J Gastric Cancer. 21:236–245. 2021.PubMed/NCBI View Article : Google Scholar |
